(Q46860946)

25 December 2017

title

Long-term glycaemic efficacy and weight changes associated with thiazolidinediones when added at an advanced stage of type 2 diabetes (English)

1 reference

25 December 2017

1 reference

Bell DS

1

1 reference

25 December 2017

Ovalle F

series ordinal

2

1 reference

25 December 2017

publication date

1 January 2006

1 reference

25 December 2017

Diabetes, Obesity and Metabolism

published in

1 reference

25 December 2017

volume

8

1 reference

25 December 2017

issue

1

1 reference

25 December 2017

page(s)

110-115

1 reference

25 December 2017

Artificially low hemoglobin A1c caused by use of dapsone.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00560.X

Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00560.X

Beta-cell rejuvenation with thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00560.X

Conversion from troglitazone to rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00560.X

The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00560.X

Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00560.X

Weight loss in patients with diabetes treated with a metformin-sulfonylurea combination in comparison with twice-daily mixed insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00560.X

Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00560.X

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00560.X

Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00560.X

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00560.X

Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-standing type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00560.X

Effect of thiazolidinediones on body weight in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00560.X

Is weight loss possible in patients treated with thiazolidinediones? Experience with a low-calorie diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00560.X

10.1111/J.1463-1326.2005.00560.X

21 January 2018

Identifiers

DOI

1 reference

25 December 2017

PubMed ID

16367889

1 reference

25 December 2017